This new CPB states that golimumab (Simponi) is considered medically necessary for the treatment of adults with any of the following conditions: (i) moderately-to-severely active rheumatoid arthritis when used in combination with methotrexate; or (ii) active psoriatic arthritis when used alone or in combination with methotrexate in members who have had an inadequate response to any one of the non-steroidal anti-inflammatory drugs (NSAIDs), and (iii) active ankylosing spondylitis with evidence of inflammatory disease in members who have had an inadequate response to NSAIDS and disease-modifying anti-rheumatic drugs (DMARDs).